Coya Therapeutics (NASDAQ:COYA – Get Free Report) and Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations.
Institutional & Insider Ownership
39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Coya Therapeutics and Oruka Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coya Therapeutics | $7.95 million | 14.34 | -$21.23 million | ($1.07) | -4.54 |
| Oruka Therapeutics | N/A | N/A | -$105.43 million | ($2.03) | -51.66 |
Coya Therapeutics has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for Coya Therapeutics and Oruka Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coya Therapeutics | 1 | 0 | 6 | 0 | 2.71 |
| Oruka Therapeutics | 1 | 0 | 10 | 0 | 2.82 |
Coya Therapeutics presently has a consensus target price of $15.33, suggesting a potential upside of 215.50%. Oruka Therapeutics has a consensus target price of $134.30, suggesting a potential upside of 28.08%. Given Coya Therapeutics’ higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Oruka Therapeutics.
Risk and Volatility
Coya Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the S&P 500.
Profitability
This table compares Coya Therapeutics and Oruka Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coya Therapeutics | -270.22% | -52.05% | -46.34% |
| Oruka Therapeutics | N/A | -21.65% | -20.88% |
Summary
Oruka Therapeutics beats Coya Therapeutics on 7 of the 13 factors compared between the two stocks.
About Coya Therapeutics
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
